# US 2025/0082598 A1 · Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082598 A1
- Document ID: US20250082598A1
- Status: Published application
- Kind: A1
- Application number: 18/576,990
- Filed: 2022-07-08
- Published: 2025-03-13
- Earliest claimed: 2021-07-08
- Assignees: NLS Pharmaceutics AG
- Applicants: NLS Pharmaceutics AG
- Inventors: Eric KONOFAL
- Web page: https://patentgrep.com/patent/US20250082598A1

## CPC

- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/221: with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns a compound of formula (I) R1=H or acyl group, preferably R1=H; R2=halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2=Cl or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating circadian rhythm sleep disorders and/or circadian rhythm sleep neurological diseases and/or any medical condition associated due to sleep deprivation.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of prevention and/or treatment of circadian rhythm sleep disorders and/or circadian rhythm sleep neurological diseases and/or any medical condition associated due to sleep deprivation and/or circadian rhythm disruption and/or central disorders of hypersomnolence, comprising the administration of a compound of formula (I)
with R1=H or an acyl group, and
R2=a halogen atom selected in the group consisting of F, Cl, Br and I, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, to a patient in need thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein R1=H.

### Claim 18 (depends on 16)

The method of claim 16, wherein R2=Cl.

### Claim 19 (depends on 16)

The method of claim 16, wherein the circadian rhythm sleep disorders are selected from the group consisting of Circadian Rhythm Sleep Disorder, Irregular Sleep-Wake Type G47.23 (ICD-10), Circadian Rhythm Sleep Disorder, Irregular Sleep-Wake Type 307.45-3 (DSM-5), Circadian Rhythm Sleep-Wake Disorder, and Irregular Sleep-Wake Rhythm Disorder 307.45-3 (ICSD-3).

### Claim 20 (depends on 16)

The method of claim 16, wherein the circadian rhythm sleep neurological diseases are selected from the group of consisting of dementia, Alzheimer's Disease, Huntington's disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

### Claim 21 (depends on 16)

The method of claim 16, wherein the circadian rhythm sleep neurological diseases are selected from the group consisting of Angelman syndrome, Williams syndrome, and Smith-Magenis syndrome.

### Claim 22 (depends on 16)

The method of claim 16, wherein the central disorders of hypersomnolence are selected from the group of Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a psychiatric disorder, hypersomnia due to a medical disorder, hypersomnia due to a medication or substance, and insufficient sleep syndrome.

### Claim 23 (depends on 16)

The method of claim 16, wherein a therapeutic dose of 0.1 mg/kg/day to 100 mg/kg/day is administrated to the patient in need thereof.

### Claim 24 (depends on 16)

The method of claim 16, wherein R2 is in para position.

### Claim 25 (depends on 16)

A method of prevention and/or treatment of circadian rhythm sleep disorders and/or circadian rhythm sleep neurological diseases and/or any medical condition associated due to sleep deprivation and/or circadian rhythm disruption and/or central disorders of hypersomnolence, comprising the administration of a pharmaceutical composition comprising a compound of formula (I) as defined in claim 16 or a pharmaceutically acceptable isomer, salt, and/or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim 26 (depends on 25)

The method of claim 25, wherein the circadian rhythm sleep disorders are selected from the group consisting of Circadian Rhythm Sleep Disorder, Irregular Sleep-Wake Type G47.23 (ICD-10), Circadian Rhythm Sleep Disorder, Irregular Sleep-Wake Type 307.45-3 (DSM-5); Circadian Rhythm Sleep-Wake Disorder, and Irregular Sleep-Wake Rhythm Disorder 307.45-3 (ICSD-3).

### Claim 27 (depends on 25)

The method of claim 25, wherein the circadian rhythm sleep neurological diseases are selected from the group consisting of dementia, Alzheimer's Disease, Huntington's disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

### Claim 28 (depends on 25)

The method of claim 25, wherein the circadian rhythm sleep neurological diseases are selected from the group consisting of Angelman syndrome, Williams syndrome, and Smith-Magenis syndrome.

### Claim 29 (depends on 25)

The method of claim 25, wherein the central disorders of hypersomnolence are selected from the group consisting of Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a psychiatric disorder, hypersomnia due to a medical disorder, hypersomnia due to a medication or substance, and insufficient sleep syndrome.

### Claim 30 (depends on 25)

The method of claim 25, wherein the pharmaceutical composition comprises from 1 mg to 800 mg of the compound of formula (I).

### Claim 31 (depends on 25)

The method of claim 25, wherein the pharmaceutical composition comprises from 20 mg to 400 mg of the compound of formula (I).

### Claim 32 (depends on 25)

The method of claim 25, wherein the pharmaceutical composition is suitable for oral or parenteral administration.

### Claim 33 (depends on 25)

The method of claim 25, wherein the pharmaceutical composition is in the form of a solution, a tablet, a capsule, or a transdermal delivery system.

### Claim 34 (depends on 33)

The method of claim 33, wherein the pharmaceutical composition is in the form of an injectable solution.
